GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00063154
- Locations
- 🇺🇸
Memorial-Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
- Conditions
- Macular Degeneration
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT00061594
- Locations
- 🇺🇸
Doheny Eye Institute, Los Angeles, California, United States
🇺🇸Midwest Retina, Columbus, Ohio, United States
🇺🇸Wills Eye Hospital, Philadelphia, Pennsylvania, United States
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
- Conditions
- Renal Cell Cancer
- First Posted Date
- 2003-05-23
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00061178
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2015-06-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00058539
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT00058552
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
- Conditions
- Macular Degeneration
- First Posted Date
- 2003-03-26
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 720
- Registration Number
- NCT00056836
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
- Conditions
- Age-Related Maculopathy
- First Posted Date
- 2003-03-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT00056823
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2002-10-18
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00047762
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Indiana University Cancer Pavilion, Indianapolis, Indiana, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2002-10-17
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00047736
- Locations
- 🇺🇸
Multinational Sites, Denver, Colorado, United States
🇺🇸Trial Information Center, Denver, Colorado, United States
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
- Conditions
- Neoplasms
- First Posted Date
- 2001-11-16
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00027027
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States